Stockholders Approve Equity Plan Amendment Expanding Share Pool Base for Future Dilution

summarizeSummary

Climb Bio's stockholders approved an amendment to its equity incentive plan that will increase the potential for future share dilution by including pre-funded warrants in the annual share pool calculation.

check_boxKey Events

• Equity Incentive Plan Amendment Approved

  Stockholders approved an amendment to the 2021 Equity Incentive Plan, which was previously outlined in a preliminary proxy statement on 2026-04-10.

• Expanded Share Pool Calculation Base

  The amendment includes pre-funded warrants in the calculation of the automatic annual share pool increase (5% of outstanding common stock plus pre-funded warrants), effective from January 1, 2027. This will lead to a larger number of shares being added to the incentive pool annually, increasing potential future dilution.

• Director Removal Proposal Rejected

  Stockholders did not approve an amendment to the Company's Certificate of Incorporation related to the removal of directors for 'cause'.

• Director Elections and Auditor Ratification

  Stockholders elected Alexander (Bo) Cumbo and Douglas Williams, Ph.D., to the Board of Directors for three-year terms and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.

auto_awesomeAnalysis

Stockholders approved a critical amendment to the 2021 Equity Incentive Plan. This amendment significantly expands the base for the automatic annual share pool increase by including pre-funded warrants in the calculation, alongside outstanding common stock. This change, effective from January 1, 2027, means a larger number of shares will be added to the incentive plan pool each year (5% of the combined total), increasing the potential for future dilution for existing shareholders. The rejection of a proposal to amend director removal for 'cause' is also notable, indicating shareholder pushback on certain governance changes.